Where are we today with personalized medicine? This article takes a good look at where the delays lie, it's not lack of technology, but rather some other additional factors that come in to play...drug companies don't want to lose potential revenue or market share, insurers say this is experimental, and the patients in the long run don't want to be left holding the bag paying or worrying that this could lead to denial of insurance coverage...and then there's the training needed to get the physicians on board with all the tools and knowledge they need....BD
Three years ago, the U.S. Food and Drug Administration issued guidelines to encourage drug companies to pursue personalized medicine – genetic testing that would determine what course of treatment, exactly, was right for a given individual.
Sounds great, right? Instead of having to try this blood pressure medication or that, you could simply take a one-time test that would tell you which blood pressure drug would be most effective at controlling your hypertension while, at the same time, carrying the lowest risk of side effects.
Yet three major obstacles have prevented the widespread use of such testing: drug companies, insurers and patients.
0 comments :
Post a Comment